Literature DB >> 12640449

Alzheimer disease's double-edged vaccine.

S M Greenberg, B J Bacskai, B T Hyman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12640449     DOI： 10.1038/nm847

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  14 in total

1.  Vaccine trial in Alzheimer's disease is halted.

Authors:  Karen Marder
Journal:  Curr Neurol Neurosci Rep       Date:  2003-09       Impact factor: 5.081

2.  Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease.

Authors:  Karl Herrup; Maria C Carrillo; Dale Schenk; Angela Cacace; Susan Desanti; Robert Fremeau; Ratan Bhat; Marcie Glicksman; Patrick May; Russell Swerdlow; Linda J Van Eldik; Lisa J Bain; Samantha Budd
Journal:  Alzheimers Dement       Date:  2013-07       Impact factor: 21.566

3.  A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; James A Ripellino; Yongsheng Li; Stephen D Schmidt; Paul M Mathews; John D Fryer; David M Holtzman; Einar M Sigurdsson; Thomas Wisniewski
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

Review 4.  Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial.

Authors:  Tyler A Kokjohn; Alex E Roher
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-04       Impact factor: 4.388

Review 5.  Memory loss in Alzheimer's disease: implications for development of therapeutics.

Authors:  Carl A Gold; Andrew E Budson
Journal:  Expert Rev Neurother       Date:  2008-12       Impact factor: 4.618

6.  Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders.

Authors:  R Lee Mosley; Howard E Gendelman
Journal:  Exp Neurol       Date:  2010-01-04       Impact factor: 5.330

7.  Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial.

Authors:  A Viswanathan; S Raj; S M Greenberg; M Stampfer; S Campbell; B T Hyman; M C Irizarry
Journal:  Neurology       Date:  2009-01-20       Impact factor: 9.910

8.  CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation.

Authors:  D Obregon; H Hou; Y Bai; W V Nikolic; T Mori; Deyan Luo; J Zeng; J Ehrhart; F Fernandez; D Morgan; B Giunta; T Town; J Tan
Journal:  Neurobiol Dis       Date:  2007-10-16       Impact factor: 5.996

9.  In vivo detection of amyloid-β deposits using heavy chain antibody fragments in a transgenic mouse model for Alzheimer's disease.

Authors:  Rob J A Nabuurs; Kim S Rutgers; Mick M Welling; Athanasios Metaxas; Maaike E de Backer; Maarten Rotman; Brian J Bacskai; Mark A van Buchem; Silvère M van der Maarel; Louise van der Weerd
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

Review 10.  Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review.

Authors:  Hannah A D Keage; Roxanna O Carare; Robert P Friedland; Paul G Ince; Seth Love; James A Nicoll; Stephen B Wharton; Roy O Weller; Carol Brayne
Journal:  BMC Neurol       Date:  2009-01-13       Impact factor: 2.474
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.